{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00018167", "CSN": null, "TRF": "ORD_1269426_01", "MRN": "44954598", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1010063", "clinicalId": "1011447", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1269426_01", "SampleName": "US1223968.01", "Version": "0", "Sample": {"FM_Id": "ORD_1269426_01", "SampleId": "US1223968.01", "BlockId": "S107-36281E", "TRFNumber": "ORD_1269426_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2021_12_28", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "60", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98146", "MRN": "44954598", "FullName": "\u6797\u5ef6\u5a01", "FirstName": "Yen_Wei", "LastName": "Lin", "SubmittedDiagnosis": "Seminoma, Testis", "Gender": "Male", "DOB": "1993_03_30", "OrderingMD": "\u5f35\u7267\u65b0", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Testis", "CollDate": "2018_09_20", "ReceivedDate": "2022-01-17 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Germ cell tumor"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "21", "clinicalTrialCount": "26", "resistiveCount": "0", "sensitizingCount": "4"}, "VariantProperties": {"VariantProperty": [{"geneName": "BARD1", "isVUS": "true", "variantName": "G82V"}, {"geneName": "C11orf30 (EMSY)", "isVUS": "true", "variantName": "S1076G"}, {"geneName": "CDKN1B", "isVUS": "true", "variantName": "amplification"}, {"geneName": "CEBPA", "isVUS": "true", "variantName": "A358G"}, {"geneName": "ERBB4", "isVUS": "true", "variantName": "E133K"}, {"geneName": "FLT1", "isVUS": "true", "variantName": "P470H"}, {"geneName": "MST1R", "isVUS": "true", "variantName": "V670G"}, {"geneName": "PDGFRA", "isVUS": "true", "variantName": "rearrangement"}, {"geneName": "PIK3C2B", "isVUS": "true", "variantName": "H1145L"}, {"geneName": "PIK3C2G", "isVUS": "true", "variantName": "amplification"}, {"geneName": "PTPRO", "isVUS": "true", "variantName": "amplification"}, {"geneName": "RAD52", "isVUS": "true", "variantName": "amplification"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CCND2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "CCND2 encodes the protein cyclin D2, which binds and regulates the cyclin_dependent kinases that control cell cycle progression, and is a downstream target of cancer signaling pathways including hedgehog and PI3K (Katoh and Katoh, 2009; 19860666, White et al., 2006; 16301994). CCND2 has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). CCND2 in germ cell neoplasms has been most extensively studied in the context of testicular germ cell tumors. The amplification of the chromosomal region that includes CCND2 has been reported in at least 10% of testicular germ cell tumors (Rodriguez et al., 2003; 12660824, Korkola et al., 2006; 16424014, Skotheim et al., 2006; 17167184). Overexpression of CCND2, at an average of 8_fold, has been reported in 69% (31/45) to 83% (25/30) of testicular germ cell tumors, and CCND2 was reported to be one of the six most highly overexpressed genes in this tumor type (Schmidt et al., 2001; 11358847, Skotheim et al., 2006; 17167184, Kukoski et al., 2003; 12777997). Published data investigating the prognostic implications of CCND2 in germ cell tumors are limited (PubMed, Mar 2021). Although preclinical studies suggest that cyclin D2 activates CDK4/6 (Busk et al., 2005; 15707582, Busk, 2003; 12695654), it is unknown whether CCND2 amplification or activating mutation predicts response to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib. Clinical studies of CDK4/6 inhibitors have shown the most promise for estrogen receptor_positive breast cancer (Finn et al., 2014; 25524798, DeMichele et al., 2014; 25501126).", "Include": "true", "ClinicalTrialNote": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04594005", "Include": "true"}, {"nctId": "NCT03099174", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT02896335", "Include": "true"}, {"nctId": "NCT03310879", "Include": "true"}, {"nctId": "NCT03065062", "Include": "true"}, {"nctId": "NCT03454035", "Include": "true"}, {"nctId": "NCT02897375", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "KIT", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "KIT (also called c_KIT) encodes a cell surface tyrosine kinase receptor that, upon ligand binding and dimerization, activates the PI3K_AKT and RAS_MAPK signaling pathways (Linnekin, 1999; 10582339). KIT aberrations, including point mutations, translocations, amplification, and overexpression, have been associated with various malignancies, and KIT is considered an oncoprotein (Fletcher, 2004; 15175998). KIT has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). KIT amplification was reported in 21% of seminoma and 9% of nonseminoma germ cell tumors (McIntyre et al., 2005; 16166280). In seminoma, KIT amplification was reported to be associated with increased gene expression (McIntyre et al., 2005; 16166280). KIT gene expression was reported to be increased in seminoma compared with non_seminoma (McIntyre et al., 2005; 16166280). In the Testicular Germ Cell TCGA and the Germ Cell Tumors MSKCC datasets, KIT amplification has been observed in 2.0% (3/149) and 2.2% (4/180) of cases, respectively (cBioPortal, Apr 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). The prognostic significance of KIT alterations in germ cell neoplasms has not been established (PubMed, Apr 2021). On the basis of clinical evidence, primarily in GIST, AML, and systemic mastocytosis, KIT activating alterations are associated with sensitivity to KIT tyrosine kinase inhibitors including imatinib, sunitinib, sorafenib, dasatinib, nilotinib, pazopanib, regorafenib, ponatinib, midostaurin, avapritinib, and ripretinib (Heinrich et al., 2014; ASCO Abstract 10506, Heinrich et al., 2017; ASCO Abstract 11011, DeAngelo et al., 2017; ASH Abstract 2, Evans et al., 2017; 29093181, Abbaspour Babaei et al., 2016; 27536065, Ramaswamy et al., 2016; 27563456, Demetri et al., 2013; 23177515, Gotlib et al., 2016; 27355533, Jawhar et al., 2017; 28424161, Xu et al., 2014; 25031773, Gotlib et al., 2005; 15972446, George et al., 2018; ASCO Abstract 11511). The use of mTOR inhibitors as an alternative therapeutic strategy has demonstrated limited success in KIT_mutated, imatinib_resistant melanoma, with 1 PR and 3 SD observed for 4 patients treated with everolimus (Si et al., 2012; ASCO Abstract 8562, Si et al., 2012; 22162580). However, no responses were observed for 10 patients with mastocytosis following everolimus monotherapy, with 8/10 patients harboring the KIT D816V mutation (Parikh et al., 2010; 20038218). The role of KIT amplification as a biomarker for response to mTOR inhibitors has not been investigated (PubMed, Mar 2021). Clinical benefit has been observed for patients with KIT amplified or overexpressing tumors following treatment with imatinib (Wei et al., 2019; 30075827, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685, Guo et al., 2011; 21690468, Debiec_Rychter et al., 2005; 15685537, DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Hotte et al., 2005; 15659505, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Reardon et al., 2009; 19904263), nilotinib (Lee et al., 2015; 26424760), sorafenib (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), and sunitinib (Minor et al., 2012; 22261812, Mahipal et al., 2012; 23114504), suggesting that KIT amplification may be sensitive to these inhibitors. However, evidence demonstrating clinical benefit for regorafenib, dasatinib, pazopanib, or ponatinib in the context of KIT amplified or overexpressing tumors is limited.", "Include": "true", "ClinicalTrialNote": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Nilotinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Nilotinib targets tyrosine kinases such as ABL (including BCR_ABL), PDGFRs, KIT, CSF1R, DDR1, and DDR2. It is FDA approved to treat newly diagnosed pediatric or adult patients with Philadelphia chromosome_positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with Ph+ CML in chronic or accelerated phase with resistance or intolerance to prior therapy including imatinib, and pediatric patients with Ph+ CML in chronic phase with resistance or intolerance to prior tyrosine_kinase inhibitor therapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Lee et al., 2015; 26424760, Carvajal et al., 2015; 25695690, Hochhaus et al., 2015; 26002753, Blay et al., 2015; 25882987, Kaijimoto et al., 2015; 26722383), KIT_amplified (Lee et al., 2015; 26424760), or KIT_expressing tumors (Sako et al., 2014; 25221952), KIT activating alterations may confer sensitivity to nilotinib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of nilotinib for the treatment of germ cell tumors are limited (PubMed, Nov 2021). Nilotinib has been primarily investigated as a therapeutic option for the treatment of CML or gastrointestinal stromal tumors (GIST). In the context of CML, a Phase 3 clinical trial of Ph+ patients treated with imatinib or nilotinib (300 mg or 400 mg) reported progression_free survival (PFS) rates of 93% and 97_98% and overall survival (OS) rates of 93% and 94_97%, respectively, at 4 years (Hughes et al., 2014; 24335106). For imatinib_resistant Japanese patients with CML, a Phase 2 trial reported a 47.8% major medical response rate to treatment with nilotinib at 12 months (Takahashi et al., 2014; 24650752). A Phase 3 clinical trial of single_agent nilotinib in 240 patients with advanced GIST who failed prior treatment with imatinib or sunitinib reported no significant difference in progression_free survival between nilotinib and the best supportive care, but did report increased overall survival for nilotinib_treated patients (Reichardt et al., 2012; 22357255). A Phase 2 trial has shown that nilotinib was well tolerated and suggested it may be particularly useful for treating patients with GIST harboring mutations in KIT exon 17 (Cauchi et al., 2012; 22119758). Preclinical, cell_based assays have reported efficacy for nilotinib alone and in combination with additional therapies in the context of leiomyosarcoma and synovial sarcoma (Villar et al., 2012; 22662203). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Sunitinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Sunitinib is a small_molecule tyrosine kinase inhibitor that targets PDGFRs, VEGFRs, KIT, FLT3, CSF_1R, and RET. It is FDA approved for the treatment of advanced or metastatic pancreatic neuroendocrine tumors, gastrointestinal stromal tumors (GISTs) in patients who have progressed on or are intolerant to imatinib, and advanced renal cell carcinoma (RCC) as well as for the adjuvant treatment of patients at high risk of recurrent RCC after nephrectomy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Minor et al., 2012; 22261812, Heinrich et al., 2008; 18955458, Buchbinder et al., 2015; 26264378, Reichardt et al., 2016; 26772734, Hirai et al., 2016; 27073655, Goemans et al., 2010; 20435347) or KIT_expressing tumors (Mahipal et al., 2012; 23114504, Minor et al., 2012; 22261812), KIT activating alterations may predict sensitivity to sunitinib. </p> <p><b>Supporting Data:</b> One study of sunitinib in cisplatin_refractory or multiply relapsed germ cell tumors reported a total response rate of 13% in 33 patients, including three confirmed partial responses (PR) and one unconfirmed PR (Oechsle et al., 2011; 21415240). However, a Phase 2 trial of sunitinib in patients with relapsed or refractory germ cell tumors found no objective responses in ten patients, with five cases of stable disease and five exhibiting progressive disease (Feldman et al., 2010; 19547919). A case study has reported an exceptional response to sunitinib in a patient with RET_amplified germ cell tumor (Subbiah et al., 2014; 25085632). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Sorafenib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Quint\u00e1s_Cardama et al., 2008; 18936790, Bisagni et al., 2009; 19461405, Handolias et al., 2010; 20372153, Disel et al., 2011; 20970876, Park et al., 2012; 22270258, Catania et al., 2014; 24855380, Guo et al., 2007; 17699867, Hu et al., 2008; 18483300) or KIT_expressing tumors (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), KIT activating alterations may predict sensitivity to sorafenib. </p> <p><b>Supporting Data:</b> In a Phase 2 study for patients with relapsed or refractory testicular germ cell tumors, none of the 18 patients experienced a PR or CR, but 3 experienced SD lasting >11 months (Skoneczna et al., 2014; ASCO Abstract 367). One patient with a KRAS_amplified testicular germ cell tumor who was refractory to chemotherapy and immunotherapy experienced CRs and PRs in metastatic lesions in the lung and brain upon treatment with the combination of carboplatin, paclitaxel, and sorafenib (Lian et al., 2019; 31492770). Phase 2 studies in non_small cell lung cancer (NSCLC) report that single_agent sorafenib improved disease control rates and that the addition of sorafenib to erlotinib increased survival in EGFR wild_type patients (Wakelee et al., 2012; 22982658, Spigel et al., 2011; 21576636). A Phase 1 trial of everolimus combined with sorafenib reported 11% partial responses and 77% stable disease (You et al., 2016; ASCO Abstract 2532). In the context of small cell lung carcinoma, sorafenib combined with cisplatin plus etoposide was highly toxic and ineffective (Sharma et al., 2014; 24420556). In HER2_negative breast cancer, Phase 2b trials found improved progression_free survival for sorafenib added to capecitabine, but not when added to paclitaxel (Baselga et al., 2012; 22412143, Gradishar et al., 2012; 22954665). Phase 2 studies of sorafenib in biliary tract cancer reported disease control rates of 33_39% (Bengala et al., 2010; 19935794). Three patients with cholangiocarcinoma derived clinical benefit from sorafenib (Qun and Tao, 2010; 20698202, LaRocca et al., 2007; 19089671). However, the addition of sorafenib to gemcitabine did not improve outcome in patients with biliary tract tumors compared with gemcitabine alone (Moehler et al., 2014; 25446376). A Phase 2 study of sorafenib and bicalutamide in castration_resistant prostate cancer (CRPC) observed a PSA response or stable disease (>6 months) in 47% (18/39) of patients (Beardsley et al., 2012; 21785998). Single_agent sorafenib was moderately active as second_line treatment for CRPC (3.7 months PFS and 18.0 months OS) (Aragon_Ching et al., 2009; 19154507). For the treatment of glioblastoma or high_grade gliomas, sorafenib alone or combined with temozolomide/radiotherapy or erlotinib did not show efficacy (Reardon et al., 2011; 20443129, Lee et al., 2012; 23099651, Peereboom et al., 2013; 23328813, Hottinger et al., 2014; 24786603). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Imatinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Carvajal et al., 2011; 21642685, Debiec_Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT_amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT_expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib (Frenard et al., 2016; 27051816). </p> <p><b>Supporting Data:</b> Although a Phase 2 trial of imatinib in chemotherapy_refractory germ cell tumors expressing KIT reported no significant clinical benefit (Einhorn et al., 2006; 16462496), two case studies have reported responses of KIT_expressing testicular seminomas to imatinib, including one complete response for 28 months (Pedersini et al., 2007; 17976614, Okamura et al., 2010; 20080832). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT02461849", "Include": "true"}, {"nctId": "NCT03564691", "Include": "true"}, {"nctId": "NCT04008797", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT04729348", "Include": "true"}, {"nctId": "NCT03711058", "Include": "true"}, {"nctId": "NCT04449549", "Include": "true"}, {"nctId": "NCT03065062", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). In numerous cancer type_specific studies as well as a large_scale pan_cancer analysis, KRAS amplification was shown to correlate with increased expression (McIntyre et al., 2005; 16354586, Mita et al., 2009; 19545448, Birkeland et al., 2012; 23099803, Chen et al., 2014; 24874471). Additionally, KRAS amplification correlated with sensitivity of cancer cell lines to KRAS knockdown, suggesting that amplified KRAS is an oncogenic driver (Chen et al., 2014; 24874471). KRAS in germ cell neoplasms has been most extensively studied in the context of testicular germ cell tumors. KRAS amplification and mutation have been observed in 8.1_20.0% and 0.0_40.0% of testicular germ cell tumors, respectively (cBioPortal, Feb 2021)(cBio_Bagrodia et al., 2016; 27646943, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Goddard et al., 2007; 17573850, McIntyre et al., 2005; 16354586, Moul et al., 1992; 1381946). KRAS mutations have been infrequently reported in ovarian germ cell tumors, but have been identified in malignant tumors arising from teratomas (Li et al., 2014; 25297496, Hershkovitz et al., 2013; 24422958, Stanojevic et al., 2012; 22682753). KRAS amplification and mutation have been linked to invasive growth of testicular germ cell tumors but were found not to provide predictive information regarding response to therapy and patient survival (Mayer et al., 2011; 20955261, Honecker et al., 2009; 19289622, Roelofs et al., 2000; 11021820). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). Clinical evidence that KRAS amplification in the absence of a concurrent KRAS activating mutation is sensitive to MEK inhibitors is limited. A Phase 2 study of selumetinib plus docetaxel in patients with gastric cancer reported 1/2 patients with KRAS amplification experienced a PR (Lee et al., 2018; ASCO Abstract 4061). A patient with cervical cancer harboring both KRAS and PIK3CA amplification treated with the combination of trametinib and the AKT inhibitor GSK2141795 achieved a SD (Lui et al., 2019; 31118140).", "Include": "true", "ClinicalTrialNote": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03989115", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03905148", "Include": "true"}, {"nctId": "NCT02407509", "Include": "true"}, {"nctId": "NCT04800822", "Include": "true"}, {"nctId": "NCT02070549", "Include": "true"}, {"nctId": "NCT03162627", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PDGFRA", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "PDGFRA encodes platelet_derived growth factor receptor alpha (PDGFR_alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). Amplification of PDGFRA, frequently occurring with amplification of the genes KDR and KIT, has been associated with increased PDGFRA expression (Burford et al., 2013; 23990986, Flavahan et al., 2016; 26700815, Roszik et al., 2016; 26787600, Verhaak et al., 2010; 20129251) and poor prognosis (Burford et al., 2013; 23990986, Koschmann et al., 2016; 27582545, Phillips et al., 2013; 23438035, Puget et al., 2012; 22389665) in some subtypes of glioma. PDGFRA amplification has been reported in 1.7% of testicular germ cell tumors (cBio_Bagrodia et al., 2016; 27646943, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In a study of 49 central nervous system germinomas, amplification of 4q12, the region where PDGFRA is located, was reported in 1 pineal gland germinoma (Schulte et al., 2016;27391150). One study reported that PDGFRA gene expression was not associated with PDGFRA amplification in germ cell tumors (McIntyre et al., 2005; 16166280). Amplification of PDGFRA or 4q12 was not reported in a study of 87 ovarian germ cell tumors (Nieuwenhuysen et al., 2018;30170975). The frequency of PDGFRA amplification in mediastinal germinomas and retroperitoneal germ cell tumors has not been evaluated (cBioPortal, PubMed, Nov 2021) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of PDGFRA alterations in germ cell tumors are limited (PubMed, Nov 2018). Published data investigating the prognostic implications of PDGFRA alterations in germ cell tumors are limited (PubMed, Jul 2021). On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib (Arefi et al., 2012; 22806436, Baccarani et al., 2007; 17666373, Cassier et al., 2012; 22718859, Chalmers et al., 2015; 25658984, Cools et al., 2003; 12660384, Curtis et al., 2007; 17555450, Debiec_Rychter et al., 2016; 15010069, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Florian et al., 2006; 16406018, Frenard et al., 2016; 27051816, Griffin et al., 2003; 12808148, Heinrich et al., 2003; 14645423, Helbig et al., 2009; 19120352, Helbig et al., 2014; 24009127, Hus et al., 2011; 21093052, Ikezoe et al., 2010; 20303172, Intermesoli et al., 2009; 19735261, Jain et al., 2009; 19013640, Jovanovic et al., 2007; 17299092, Kang et al., 2012; 22150077, Klion et al., 2004; 14504092, Kobayashi et al., 2009; 19192229, Koc\u00e1kov\u00e1 et al., 2014; 24635438, Metzgeroth et al., 2008; 18950453, Murayama et al., 2012; 22645636, Ogbogu et al., 2009; 19910029, Ohnishi et al., 2006; 16856885, Pardanani et al., 2003; 12842979, Pardanani et al., 2004; 15284118, Qu et al., 2016; 27120808, Score et al., 2006; 16498388, Shah et al., 2011; 24669761, Sugimoto et al., 2015; 26319757, Volz et al., 2011; 20609486, von Bubnoff et al., 2005; 15618966, Walz et al., 2006; 16845659, Yoo et al., 2016; 26130666). Sorafenib has shown clinical and preclinical activity against the FIP1L1_PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)(Fumagalli et al., 2012; ESMO Abstract 1491P, Al_Riyami et al., 2013; 23157309, Lierman et al., 2006; 16645167, Lierman et al., 2009; 19212337, Metzgeroth et al., 2012; 21818111, Roubaud et al., 2012; 22294526, Von Bubnoff et al., 2011; 20972453). Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1_PDGFRA or activating mutations (Hochhaus et al., 2013; 24057647, Ikezoe et al., 2010; 20303172, Tabouret et al., 2011; 20832858); preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST (Dewaele et al., 2008; 18794084, Weisberg et al., 2006; 17087936). Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib (Heinrich et al., 2006; ASCO Abstract 9502, Brohl et al., 2015; 26396737) or regorafenib (Grellety et al., 2015; 28031906, Kollar et al., 2014; 25905001). Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1_PDGFRA fusion to dasatinib (Dewaele et al., 2008; 18794084, Lierman et al., 2009; 19212337). PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical (Heinrich et al., 2017; ASCO Abstract 11011, Evans et al., 2017; 29093181) and preclinical (Evans et al., 2017; 29093181) studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient (Jaku et al., 2017; ASCO Abstract 2515).", "Include": "true", "ClinicalTrialNote": "PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Imatinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Carvajal et al., 2011; 21642685, Debiec_Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT_amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT_expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib (Frenard et al., 2016; 27051816). </p> <p><b>Supporting Data:</b> Although a Phase 2 trial of imatinib in chemotherapy_refractory germ cell tumors expressing KIT reported no significant clinical benefit (Einhorn et al., 2006; 16462496), two case studies have reported responses of KIT_expressing testicular seminomas to imatinib, including one complete response for 28 months (Pedersini et al., 2007; 17976614, Okamura et al., 2010; 20080832). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": {"nctId": "NCT01738139", "Include": "true"}}}}, "ReferenceLinks": null}, {"Name": "FGF23", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "FGF23 encodes a member of the fibroblast growth factor protein family that plays a central role in phosphate homeostasis (Jonsson et al., 2003; 12711740). Overexpression of FGF23 by tumor cells can cause hypophosphatemia through excessive renal phosphate clearance (Shimada et al., 2001; 11344269), while germline gain_of_function (protein stabilizing) mutations in FGF23 cause autosomal dominant hypophosphatemic rickets (Xu and White, 2005; 15863037). FGF23 alterations have been reported with highest incidence in uterine carcinosarcoma (7.0%), ovarian carcinoma (6.5%), testicular germ cell cancer (5.4%), cutaneous melanoma (5.0%), low_grade glioma (4.9%), lung squamous cell carcinoma (4.5%), sarcoma (4.3%), colorectal adenocarcinoma (4.2%), lung adenocarcinoma (3.7%), and head and neck squamous cell carcinoma (3.4%) (cBioPortal, 2022) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). There are no targeted therapies that directly address genomic alterations in FGF23. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FGF6", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "FGF6 (also known as HST_2) encodes a member of the fibroblast growth factor protein family and is hypothesized to play a role in muscle tissue regeneration (Neuhaus et al., 2003; 12917328) by signaling through FGFR4, and to a lesser extent FGFR1 and FGFR2 (Ornitz et al., 1996; 8663044). FGF6 expression has been observed in several cancers (Iida et al., 1992; 1549352, Ropiquet et al., 2000; 10945637, Niini et al., 2002; 12399964) and was shown to be oncogenic in preclinical models (Marics et al., 1989; 2649847, Iida et al., 1992; 1549352). FGF6 has been reported as amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). Somatic alterations affecting FGF6 are infrequently documented, with the highest rates reported in penile cancer (4%), cutaneous melanoma (1_3%), stomach carcinoma (1_3%) and colorectal cancer (1%) (cBioPortal, COSMIC, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Amplification of FGF6 has been frequently observed in testicular germ cell cancer (5%) and ovarian serous cystadenocarcinoma (5%), and in 2_6% of lower_grade gliomas, glioblastomas, sarcomas, breast invasive carcinomas, uterine carcinosarcomas, lung squamous cell carcinomas (SCC), head and neck SCC, pancreatic adenocarcinomas, and esophageal carcinomas (cBioPortal, Jan 2022) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). FGF6 is co_localized with FGF23 and CCND2 at chromosomal locus 12p13 and has been reported to be co_amplified with these genes in 1.3% of patients with breast cancer (Parish et al., 2015; 25950492). FGF6 expression has been reported in 54% (14/26) of prostate cancer samples, which also frequently express FGFR4 (Ropiquet et al., 2000; 10945637). FGF6 expression has also been observed in 71% (12/17) of patients with childhood acute lymphoblastic leukemia (Niini et al., 2002; 12399964). There are no targeted therapies that directly address genomic alterations in FGF6. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "KDR", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "KDR encodes vascular endothelial growth factor receptor 2 (VEGFR2), a member of the vascular endothelial growth factor receptor (VEGFR) family. It is a receptor tyrosine kinase that transmits signals from VEGFA and is involved in both tumor angiogenesis and vasculogenesis during development (Takahashi, 2011; 22130231). KDR amplification has been reported in many tumor types and may be oncogenic (Takahashi, 2011; 22130231). KDR amplification has been reported in 2.2% of testicular germ cell tumors (cBio_Bagrodia et al., 2016; 27646943, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In a study of 49 central nervous system germinomas, amplification of 4q12, the region where KDR is located, was reported in 1 pineal gland germinoma (Schulte et al., 2016;27391150). Amplification of KDR or 4q12 was not reported in a study of 87 ovarian germ cell tumors (Nieuwenhuysen et al., 2018;30170975). The frequency of KDR amplification in mediastinal germinomas and retroperitoneal germ cell tumors has not been evaluated (cBioPortal, PubMed, Nov 2021) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of KDR alterations in germ cell tumors are limited (PubMed, Nov 2021). On the basis of clinical benefit for patients with ccRCC (Beuselinck et al., 2018; 29095068, Song et al., 2015; 26228213, Dornbusch et al., 2013; 24086736, Terakawa et al., 2013; 21478036, You et al., 2015; 24710685) and a patient with breast angiosarcoma (Silva et al., 2015; 25639617), high VEGFR_2 expression has been associated with sensitivity to sunitinib. However, because data supporting concordance between VEGFR_2 expression and KDR genomic biomarkers are limited, it is unclear whether these therapeutic strategies would be beneficial in this case. On the basis of extensive clinical evidence across multiple tumor types, expression of plasma or tumor VEGFR_1 or VEGFR_2 has not been established as a reliable biomarker to predict response to the VEGFA_targeted agent bevacizumab (Baumgarten et al., 2016; 26627848, Sathornsumetee et al., 2008; 18182667, Olafson et al., 2019; 31582283, Nishikawa et al., 2013; ASCO Abstract 2023, Wick et al., 2013; WCN Abstract 1207, Duda et al., 2010; 20484123, Stremitzer et al., 2016; 27535973, Weickhardt et al., 2015; 26125443, Kopetz et al., 2009; 20008624, Miles et al., 2013; 23422754, Fountzilas et al., 2011; 21868552, Gianni et al., 2013; 23569311, S\u00e1nchez_Rovira et al., 2013; 23397155, Cameron et al., 2013; 23932548, Mok et al., 2014; 24807156, An et al., 2014; 24577128, Bais et al., 2017; 29059426, Cohen et al., 2009; 19201650, Van Cutsem et al., 2011; EMCC Abstract 803, Van Cutsem et al., 2012; 22565005, Lee et al., 2018; 29941486, Xu et al., 2009; 19826039, Heist et al., 2014; 25605928).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI positivity at any level has been reported in 0_31% (n = 17_188) of testicular germ cell tumors (GCTs) (Lothe et al., 1993; 8261392, Murty et al., 1994; 8033127, Huddart et al., 1995; 7669575, Faulkner and Friedlander, 2000; 11006028, Devouassoux_Shisheboran et al., 2001; 11719586, Velasco et al., 2004; 15492498, Olasz et al., 2005; 16309235, Vladu\u0161i\u0107 et al., 2014; 25075023, C\u00e1rcano et al., 2016; 27153176) and in 33% (12/36) of ovarian GCTs (Faulkner and Friedlander, 2000; 11006028). Within testicular GCTs, 12_31% of cases (n = 17_51) have been classified as having low_level MSI (MSI_L) and 69_100% (n = 17_133) have been classified as MSS (Devouassoux_Shisheboran et al., 2001; 11719586, Olasz et al., 2005; 16309235, C\u00e1rcano et al., 2016; 27153176), with MSI_high (MSI_H) rarely reported; one study identified MSI_L in 6% (6/100) and MSI_H in 0% (0/100) of unselected testicular GCTs, and MSI_L in 6% (2/35) and MSI_H in 26% (9/35) of chemotherapy_resistant cases (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622). The significance of MSI in the context of GCTs is not well established (PubMed, Nov 2021). One study reported MSI_H to be significantly more frequent in chemotherapy_resistant than unselected testicular GCT cases (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622), and some studies have associated MSI positivity with reduced PFS and/or increased risk of recurrence (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622, Velasco et al., 2004; 15492498, Velasco et al., 2008; 18076065); however, another study found no correlation between MSI status and clinicopathologic features, including chemotherapy sensitivity and outcome (Olasz et al., 2005; 16309235). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Compared to other tumor types, germ cell tumors (GCTs) have been reported to have a low TMB (mean 0.51 mutations per megabase [muts/Mb] as measured in tissue), with a similar mutation rate reported for seminoma (0.50 muts/Mb) and non_seminoma (0.49 muts/Mb) tumors (Litchfield et al., 2015; 25609015). Published data investigating the prognostic implications of TMB in germ cell tumors are limited (PubMed, Sep 2021). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "CCND2", "Alteration": "amplification", "Title": "CDK4/6 Tumor, Abemaciclib, Paclitaxel", "StudyPhase": "PHASE 1/2", "Target": "CDK4, CDK6", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT04594005", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.", "StudyPhase": "PHASE 1", "Target": "CDK4, CDK6, IGF_1, IGF_2, Aromatase, ER", "Locations": "Seoul (Korea, Republic of), Goyang (Korea, Republic of), Aichi, Nagoya (Japan), Kanagawa, Isehara (Japan), Tokyo, Chuo_ku (Japan), Tokyo, Koto_ku (Japan), Chiba, Kashiwa (Japan), Helsinki (Finland), Tampere (Finland), Turku (Finland)", "NCTID": "NCT03099174", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Alaska, Washington", "NCTID": "NCT03994796", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Palbociclib In Progressive Brain Metastases", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT02896335", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D_type Cyclins or Amplification of CDK4 or CDK6", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03310879", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03065062", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MAPK3, MAPK1, CDK4, CDK6", "Locations": "North Carolina", "NCTID": "NCT03454035", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "CDK4, CDK6", "Locations": "Georgia", "NCTID": "NCT02897375", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy", "StudyPhase": "PHASE 2", "Target": "KIT, ABL", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT02461849", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)", "StudyPhase": "PHASE 1", "Target": "ITL4, FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1", "Locations": "Seoul (Korea, Republic of), Tokyo (Japan), Haifa (Israel), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Warszawa (Poland), Gdansk (Poland), Heraklion (Greece), Washington", "NCTID": "NCT03564691", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor", "StudyPhase": "PHASE 1", "Target": "CBP, Beta_catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT", "Locations": "Osakasayama (Japan), Chuo_Ku (Japan), Kashiwa (Japan)", "NCTID": "NCT04008797", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Pembrolizumab And Lenvatinib In Leptomeningeal Metastases", "StudyPhase": "PHASE 2", "Target": "PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET", "Locations": "Massachusetts", "NCTID": "NCT04729348", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti_PD_1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch_repair Proficient (MSS) Colorectal Cancer", "StudyPhase": "PHASE 1/2", "Target": "PD_1, PI3K", "Locations": "Maryland", "NCTID": "NCT03711058", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Rapid Analysis and Response Evaluation of Combination Anti_Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel", "StudyPhase": "PHASE 2", "Target": "ABL, KIT", "Locations": "Maryland", "NCTID": "NCT04449549", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03065062", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Dose_Escalation and Dose_Expansion of RMC_4630 and Cobimetinib in Relapsed/Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "SHP2, MEK", "Locations": "Seoul (Korea, Republic of), Oregon, California, Colorado, Arizona, Wisconsin, Illinois", "NCTID": "NCT03989115", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "RAFs, EGFR, MEK", "Locations": "Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas", "NCTID": "NCT03905148", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Phase I Trial of RO5126766", "StudyPhase": "PHASE 1", "Target": "RAFs, MEK, mTOR", "Locations": "London (United Kingdom), Sutton (United Kingdom)", "NCTID": "NCT02407509", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "PF_07284892 in Participants With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "SHP2, ROS1, ALK, MEK, BRAF, EGFR", "Locations": "California, Michigan, New York, Tennessee, Texas", "NCTID": "NCT04800822", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Toronto (Canada)", "NCTID": "NCT02070549", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Selumetinib and Olaparib in Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, PARP", "Locations": "Texas", "NCTID": "NCT03162627", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "amplification", "Title": "Ipilimumab and Imatinib Mesylate in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "KIT, ABL, CTLA_4", "Locations": "Texas", "NCTID": "NCT01738139", "Note": "PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "18483217", "FullCitation": "Andrae J, et al. Genes Dev. (2008) pmid: 18483217", "Include": "true"}, {"number": "1", "ReferenceId": "15175998", "FullCitation": "Semin. Oncol. (2004) pmid: 15175998", "Include": "true"}, {"number": "2", "ReferenceId": "23990986", "FullCitation": "Burford A, et al. PLoS ONE (2013) pmid: 23990986", "Include": "true"}, {"number": "3", "ReferenceId": "26700815", "FullCitation": "Flavahan WA, et al. Nature (2016) pmid: 26700815", "Include": "true"}, {"number": "4", "ReferenceId": "26787600", "FullCitation": "Roszik J, et al. Sci Rep (2016) pmid: 26787600", "Include": "true"}, {"number": "5", "ReferenceId": "20129251", "FullCitation": "Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251", "Include": "true"}, {"number": "6", "ReferenceId": "27582545", "FullCitation": "Koschmann C, et al. Oncotarget (2016) pmid: 27582545", "Include": "true"}, {"number": "7", "ReferenceId": "23438035", "FullCitation": "Phillips JJ, et al. Brain Pathol. (2013) pmid: 23438035", "Include": "true"}, {"number": "8", "ReferenceId": "22389665", "FullCitation": "Puget S, et al. PLoS ONE (2012) pmid: 22389665", "Include": "true"}, {"number": "9", "ReferenceId": "27646943", "FullCitation": "Bagrodia A, et al. J. Clin. Oncol. (2016) pmid: 27646943", "Include": "true"}, {"number": "10", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "11", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "12", "ReferenceId": "27391150", "FullCitation": "Schulte SL, et al. Oncotarget (2016) pmid: 27391150", "Include": "true"}, {"number": "13", "ReferenceId": "16166280", "FullCitation": "McIntyre A, et al. Cancer Res. (2005) pmid: 16166280", "Include": "true"}, {"number": "14", "ReferenceId": "30170975", "FullCitation": "Van Nieuwenhuysen E, et al. Gynecol. Oncol. (2018) pmid: 30170975", "Include": "true"}, {"number": "15", "ReferenceId": "22806436", "FullCitation": "Arefi M, et al. Int. J. Hematol. (2012) pmid: 22806436", "Include": "true"}, {"number": "16", "ReferenceId": "17666373", "FullCitation": "Baccarani M, et al. Haematologica (2007) pmid: 17666373", "Include": "true"}, {"number": "17", "ReferenceId": "22718859", "FullCitation": "Cassier PA, et al. Clin. Cancer Res. (2012) pmid: 22718859", "Include": "true"}, {"number": "18", "ReferenceId": "25658984", "FullCitation": "Chalmers ZR, et al. Blood Cancer J (2015) pmid: 25658984", "Include": "true"}, {"number": "19", "ReferenceId": "12660384", "FullCitation": "Cools J, et al. N. Engl. J. Med. (2003) pmid: 12660384", "Include": "true"}, {"number": "20", "ReferenceId": "17555450", "FullCitation": "Curtis CE, et al. Br. J. Haematol. (2007) pmid: 17555450", "Include": "true"}, {"number": "21", "ReferenceId": "15010069", "FullCitation": "Debiec_Rychter M, et al. Eur. J. Cancer (2004) pmid: 15010069", "Include": "true"}, {"number": "22", "ReferenceId": "20473908", "FullCitation": "Dileo P, et al. Int. J. Cancer (2011) pmid: 20473908", "Include": "true"}, {"number": "23", "ReferenceId": "24638008", "FullCitation": "Fanta PT, et al. J. Clin. Oncol. (2015) pmid: 24638008", "Include": "true"}, {"number": "24", "ReferenceId": "16406018", "FullCitation": "Florian S, et al. Leuk. Res. (2006) pmid: 16406018", "Include": "true"}, {"number": "25", "ReferenceId": "27051816", "FullCitation": "Frenard C, et al. JAAD Case Rep (2016) pmid: 27051816", "Include": "true"}, {"number": "26", "ReferenceId": "12808148", "FullCitation": "Griffin JH, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808148", "Include": "true"}, {"number": "27", "ReferenceId": "14645423", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423", "Include": "true"}, {"number": "28", "ReferenceId": "19120352", "FullCitation": "Helbig G, et al. Br. J. Haematol. (2009) pmid: 19120352", "Include": "true"}, {"number": "29", "ReferenceId": "24009127", "FullCitation": "Helbig G, et al. Am. J. Hematol. (2014) pmid: 24009127", "Include": "true"}, {"number": "30", "ReferenceId": "21093052", "FullCitation": "Hus M, et al. Leuk. Res. (2011) pmid: 21093052", "Include": "true"}, {"number": "31", "ReferenceId": "20303172", "FullCitation": "Ikezoe T, et al. Leuk. Res. (2010) pmid: 20303172", "Include": "true"}, {"number": "32", "ReferenceId": "19735261", "FullCitation": "Intermesoli T, et al. Br. J. Haematol. (2009) pmid: 19735261", "Include": "true"}, {"number": "33", "ReferenceId": "19013640", "FullCitation": "Jain N, et al. Leuk. Res. (2009) pmid: 19013640", "Include": "true"}, {"number": "34", "ReferenceId": "17299092", "FullCitation": "Jovanovic JV, et al. Blood (2007) pmid: 17299092", "Include": "true"}, {"number": "35", "ReferenceId": "22150077", "FullCitation": "Kang HJ, et al. Acta Oncol (2012) pmid: 22150077", "Include": "true"}, {"number": "36", "ReferenceId": "14504092", "FullCitation": "Klion AD, et al. Blood (2004) pmid: 14504092", "Include": "true"}, {"number": "37", "ReferenceId": "19192229", "FullCitation": "Kobayashi M, et al. Respirology (2009) pmid: 19192229", "Include": "true"}, {"number": "38", "ReferenceId": "24635438", "FullCitation": "Koc\u00e1kov\u00e1 I, et al. Klin Onkol (2014) pmid: 24635438", "Include": "true"}, {"number": "39", "ReferenceId": "18950453", "FullCitation": "Metzgeroth G, et al. Br. J. Haematol. (2008) pmid: 18950453", "Include": "true"}, {"number": "40", "ReferenceId": "22645636", "FullCitation": "Murayama Y, et al. World J Gastrointest Oncol (2012) pmid: 22645636", "Include": "true"}, {"number": "41", "ReferenceId": "19910029", "FullCitation": "Ogbogu PU, et al. J. Allergy Clin. Immunol. (2009) pmid: 19910029", "Include": "true"}, {"number": "42", "ReferenceId": "16856885", "FullCitation": "Ohnishi H, et al. Br. J. Haematol. (2006) pmid: 16856885", "Include": "true"}, {"number": "43", "ReferenceId": "12842979", "FullCitation": "Pardanani A, et al. Blood (2003) pmid: 12842979", "Include": "true"}, {"number": "44", "ReferenceId": "15284118", "FullCitation": "Pardanani A, et al. Blood (2004) pmid: 15284118", "Include": "true"}, {"number": "45", "ReferenceId": "27120808", "FullCitation": "Qu SQ, et al. Oncotarget (2016) pmid: 27120808", "Include": "true"}, {"number": "46", "ReferenceId": "16498388", "FullCitation": "Score J, et al. Leukemia (2006) pmid: 16498388", "Include": "true"}, {"number": "47", "ReferenceId": "24669761", "FullCitation": "Shah S, et al. J Hematol Oncol (2014) pmid: 24669761", "Include": "true"}, {"number": "48", "ReferenceId": "26319757", "FullCitation": "Sugimoto Y, et al. Cancer Genet (2015) pmid: 26319757", "Include": "true"}, {"number": "49", "ReferenceId": "20609486", "FullCitation": "Volz HC, et al. Int. J. Cardiol. (2011) pmid: 20609486", "Include": "true"}, {"number": "50", "ReferenceId": "15618966", "FullCitation": "von Bubnoff N, et al. Leukemia (2005) pmid: 15618966", "Include": "true"}, {"number": "51", "ReferenceId": "16845659", "FullCitation": "Walz C, et al. Genes Chromosomes Cancer (2006) pmid: 16845659", "Include": "true"}, {"number": "52", "ReferenceId": "26130666", "FullCitation": "Yoo C, et al. Cancer Res Treat (2016) pmid: 26130666", "Include": "true"}, {"number": "53", "ReferenceId": "23157309", "FullCitation": "Al_Riyami AZ, et al. Leuk. Lymphoma (2013) pmid: 23157309", "Include": "true"}, {"number": "54", "ReferenceId": "16645167", "FullCitation": "Lierman E, et al. Blood (2006) pmid: 16645167", "Include": "true"}, {"number": "55", "ReferenceId": "19212337", "FullCitation": "Lierman E, et al. Leukemia (2009) pmid: 19212337", "Include": "true"}, {"number": "56", "ReferenceId": "21818111", "FullCitation": "Metzgeroth G, et al. Leukemia (2012) pmid: 21818111", "Include": "true"}, {"number": "57", "ReferenceId": "22294526", "FullCitation": "Roubaud G, et al. Ann. Oncol. (2012) pmid: 22294526", "Include": "true"}, {"number": "58", "ReferenceId": "20972453", "FullCitation": "von Bubnoff N, et al. Oncogene (2011) pmid: 20972453", "Include": "true"}, {"number": "59", "ReferenceId": "24057647", "FullCitation": "Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2013) pmid: 24057647", "Include": "true"}, {"number": "60", "ReferenceId": "20832858", "FullCitation": "Tabouret E, et al. Leuk. Res. (2011) pmid: 20832858", "Include": "true"}, {"number": "61", "ReferenceId": "18794084", "FullCitation": "Dewaele B, et al. Clin. Cancer Res. (2008) pmid: 18794084", "Include": "true"}, {"number": "62", "ReferenceId": "17087936", "FullCitation": "Weisberg E, et al. Gastroenterology (2006) pmid: 17087936", "Include": "true"}, {"number": "63", "ReferenceId": "26396737", "FullCitation": "Brohl AS, et al. Clin Sarcoma Res (2015) pmid: 26396737", "Include": "true"}, {"number": "64", "ReferenceId": "28031906", "FullCitation": "Grellety T, et al. Future Sci OA (2015) pmid: 28031906", "Include": "true"}, {"number": "65", "ReferenceId": "25905001", "FullCitation": "Koll\u00e0r A, et al. Clin Sarcoma Res (2014) pmid: 25905001", "Include": "true"}, {"number": "66", "ReferenceId": "29093181", "FullCitation": "Evans EK, et al. Sci Transl Med (2017) pmid: 29093181", "Include": "true"}, {"number": "67", "ReferenceId": "10582339", "FullCitation": "Int. J. Biochem. Cell Biol. (1999) pmid: 10582339", "Include": "true"}, {"number": "68", "ReferenceId": "24071852", "FullCitation": "Zack TI, et al. Nat. Genet. (2013) pmid: 24071852", "Include": "true"}, {"number": "69", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "70", "ReferenceId": "27536065", "FullCitation": "Abbaspour Babaei M, et al. Drug Des Devel Ther (2016) pmid: 27536065", "Include": "true"}, {"number": "71", "ReferenceId": "27563456", "FullCitation": "Ramaswamy A, et al. J Gastrointest Oncol (2016) pmid: 27563456", "Include": "true"}, {"number": "72", "ReferenceId": "23177515", "FullCitation": "Demetri GD, et al. Lancet (2013) pmid: 23177515", "Include": "true"}, {"number": "73", "ReferenceId": "27355533", "FullCitation": "Gotlib J, et al. N. Engl. J. Med. (2016) pmid: 27355533", "Include": "true"}, {"number": "74", "ReferenceId": "28424161", "FullCitation": "Jawhar M, et al. Blood (2017) pmid: 28424161", "Include": "true"}, {"number": "75", "ReferenceId": "25031773", "FullCitation": "Xu X, et al. Int J Clin Exp Pathol (2014) pmid: 25031773", "Include": "true"}, {"number": "76", "ReferenceId": "15972446", "FullCitation": "Gotlib J, et al. Blood (2005) pmid: 15972446", "Include": "true"}, {"number": "77", "ReferenceId": "22162580", "FullCitation": "Si L, et al. J. Clin. Oncol. (2012) pmid: 22162580", "Include": "true"}, {"number": "78", "ReferenceId": "20038218", "FullCitation": "Parikh SA, et al. Leuk Lymphoma (2010) pmid: 20038218", "Include": "true"}, {"number": "79", "ReferenceId": "30075827", "FullCitation": "Wei X, et al. Oncol. Res. (2019) pmid: 30075827", "Include": "true"}, {"number": "80", "ReferenceId": "23775962", "FullCitation": "Hodi FS, et al. J. Clin. Oncol. (2013) pmid: 23775962", "Include": "true"}, {"number": "81", "ReferenceId": "21642685", "FullCitation": "Carvajal RD, et al. JAMA (2011) pmid: 21642685", "Include": "true"}, {"number": "82", "ReferenceId": "21690468", "FullCitation": "Guo J, et al. J. Clin. Oncol. (2011) pmid: 21690468", "Include": "true"}, {"number": "83", "ReferenceId": "15685537", "FullCitation": "Debiec_Rychter M, et al. Gastroenterology (2005) pmid: 15685537", "Include": "true"}, {"number": "84", "ReferenceId": "19303137", "FullCitation": "Dematteo RP, et al. Lancet (2009) pmid: 19303137", "Include": "true"}, {"number": "85", "ReferenceId": "16135502", "FullCitation": "Faivre S, et al. J. Clin. Oncol. (2005) pmid: 16135502", "Include": "true"}, {"number": "86", "ReferenceId": "15659505", "FullCitation": "Hotte SJ, et al. J. Clin. Oncol. (2005) pmid: 15659505", "Include": "true"}, {"number": "87", "ReferenceId": "15350030", "FullCitation": "Alcedo JC, et al. Head Neck (2004) pmid: 15350030", "Include": "true"}, {"number": "88", "ReferenceId": "21403650", "FullCitation": "Brandwein JM, et al. Leukemia (2011) pmid: 21403650", "Include": "true"}, {"number": "89", "ReferenceId": "19904263", "FullCitation": "Reardon DA, et al. Br. J. Cancer (2009) pmid: 19904263", "Include": "true"}, {"number": "90", "ReferenceId": "26424760", "FullCitation": "Lee SJ, et al. Oncologist (2015) pmid: 26424760", "Include": "true"}, {"number": "91", "ReferenceId": "22374331", "FullCitation": "Llovet JM, et al. Clin. Cancer Res. (2012) pmid: 22374331", "Include": "true"}, {"number": "92", "ReferenceId": "23058498", "FullCitation": "Zhang HL, et al. Clin Genitourin Cancer (2013) pmid: 23058498", "Include": "true"}, {"number": "93", "ReferenceId": "25450081", "FullCitation": "Seino S, et al. Gastroenterology (2014) pmid: 25450081", "Include": "true"}, {"number": "94", "ReferenceId": "18846437", "FullCitation": "Li XF, et al. Med. Oncol. (2009) pmid: 18846437", "Include": "true"}, {"number": "95", "ReferenceId": "22261812", "FullCitation": "Minor DR, et al. Clin. Cancer Res. (2012) pmid: 22261812", "Include": "true"}, {"number": "96", "ReferenceId": "23114504", "FullCitation": "Mahipal A, et al. Melanoma Res. (2012) pmid: 23114504", "Include": "true"}, {"number": "97", "ReferenceId": "19860666", "FullCitation": "Katoh Y, et al. Curr. Mol. Med. (2009) pmid: 19860666", "Include": "true"}, {"number": "98", "ReferenceId": "16301994", "FullCitation": "White PC, et al. Oncogene (2006) pmid: 16301994", "Include": "true"}, {"number": "99", "ReferenceId": "12660824", "FullCitation": "Rodriguez S, et al. Oncogene (2003) pmid: 12660824", "Include": "true"}, {"number": "100", "ReferenceId": "16424014", "FullCitation": "Korkola JE, et al. Cancer Res. (2006) pmid: 16424014", "Include": "true"}, {"number": "101", "ReferenceId": "17167184", "FullCitation": "Skotheim RI, et al. Cell. Oncol. (2006) pmid: 17167184", "Include": "true"}, {"number": "102", "ReferenceId": "11358847", "FullCitation": "Schmidt BA, et al. Cancer Res. (2001) pmid: 11358847", "Include": "true"}, {"number": "103", "ReferenceId": "12777997", "FullCitation": "Kukoski R, et al. Appl. Immunohistochem. Mol. Morphol. (2003) pmid: 12777997", "Include": "true"}, {"number": "104", "ReferenceId": "15707582", "FullCitation": "Busk PK, et al. Exp. Cell Res. (2005) pmid: 15707582", "Include": "true"}, {"number": "105", "ReferenceId": "12695654", "FullCitation": "Busk PK, et al. Cell Cycle () pmid: 12695654", "Include": "true"}, {"number": "106", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "107", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "108", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "109", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "110", "ReferenceId": "16354586", "FullCitation": "McIntyre A, et al. Neoplasia (2005) pmid: 16354586", "Include": "true"}, {"number": "111", "ReferenceId": "19545448", "FullCitation": "Mita H, et al. BMC Cancer (2009) pmid: 19545448", "Include": "true"}, {"number": "112", "ReferenceId": "23099803", "FullCitation": "Birkeland E, et al. Br. J. Cancer (2012) pmid: 23099803", "Include": "true"}, {"number": "113", "ReferenceId": "24874471", "FullCitation": "Chen Y, et al. PLoS ONE (2014) pmid: 24874471", "Include": "true"}, {"number": "114", "ReferenceId": "17573850", "FullCitation": "Goddard NC, et al. Int. J. Androl. (2007) pmid: 17573850", "Include": "true"}, {"number": "115", "ReferenceId": "1381946", "FullCitation": "Moul JW, et al. Genes Chromosomes Cancer (1992) pmid: 1381946", "Include": "true"}, {"number": "116", "ReferenceId": "25297496", "FullCitation": "Li Y, et al. J Ovarian Res (2014) pmid: 25297496", "Include": "true"}, {"number": "117", "ReferenceId": "24422958", "FullCitation": "Hershkovitz D, et al. Pathol. Int. (2013) pmid: 24422958", "Include": "true"}, {"number": "118", "ReferenceId": "22682753", "FullCitation": "Stanojevic B, et al. BMC Cancer (2012) pmid: 22682753", "Include": "true"}, {"number": "119", "ReferenceId": "20955261", "FullCitation": "Mayer F, et al. BJU Int. (2011) pmid: 20955261", "Include": "true"}, {"number": "120", "ReferenceId": "19289622", "FullCitation": "Honecker F, et al. J. Clin. Oncol. (2009) pmid: 19289622", "Include": "true"}, {"number": "121", "ReferenceId": "11021820", "FullCitation": "Roelofs H, et al. Am. J. Pathol. (2000) pmid: 11021820", "Include": "true"}, {"number": "122", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "123", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "124", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "125", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "126", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "127", "ReferenceId": "31118140", "FullCitation": "Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140", "Include": "true"}, {"number": "128", "ReferenceId": "22130231", "FullCitation": "Biol. Pharm. Bull. (2011) pmid: 22130231", "Include": "true"}, {"number": "129", "ReferenceId": "29095068", "FullCitation": "Beuselinck B, et al. Acta Oncol (2018) pmid: 29095068", "Include": "true"}, {"number": "130", "ReferenceId": "26228213", "FullCitation": "Song Y, et al. Chin. Med. J. (2015) pmid: 26228213", "Include": "true"}, {"number": "131", "ReferenceId": "24086736", "FullCitation": "Dornbusch J, et al. PLoS ONE (2013) pmid: 24086736", "Include": "true"}, {"number": "132", "ReferenceId": "21478036", "FullCitation": "Terakawa T, et al. Urol. Oncol. (2013) pmid: 21478036", "Include": "true"}, {"number": "133", "ReferenceId": "24710685", "FullCitation": "You D, et al. World J Urol (2015) pmid: 24710685", "Include": "true"}, {"number": "134", "ReferenceId": "25639617", "FullCitation": "Silva E, et al. Breast J () pmid: 25639617", "Include": "true"}, {"number": "135", "ReferenceId": "26627848", "FullCitation": "Baumgarten P, et al. Neuro_oncology (2016) pmid: 26627848", "Include": "true"}, {"number": "136", "ReferenceId": "18182667", "FullCitation": "Sathornsumetee S, et al. J. Clin. Oncol. (2008) pmid: 18182667", "Include": "true"}, {"number": "137", "ReferenceId": "31582283", "FullCitation": "Olafson LR, et al. J Clin Neurosci (2019) pmid: 31582283", "Include": "true"}, {"number": "138", "ReferenceId": "20484123", "FullCitation": "Duda DG, et al. Oncologist (2010) pmid: 20484123", "Include": "true"}, {"number": "139", "ReferenceId": "27535973", "FullCitation": "Stremitzer S, et al. Mol. Cancer Ther. (2016) pmid: 27535973", "Include": "true"}, {"number": "140", "ReferenceId": "26125443", "FullCitation": "Weickhardt AJ, et al. Br. J. Cancer (2015) pmid: 26125443", "Include": "true"}, {"number": "141", "ReferenceId": "20008624", "FullCitation": "Kopetz S, et al. J. Clin. Oncol. (2010) pmid: 20008624", "Include": "true"}, {"number": "142", "ReferenceId": "23422754", "FullCitation": "Miles DW, et al. Br. J. Cancer (2013) pmid: 23422754", "Include": "true"}, {"number": "143", "ReferenceId": "21868552", "FullCitation": "Fountzilas G, et al. Anticancer Res. (2011) pmid: 21868552", "Include": "true"}, {"number": "144", "ReferenceId": "23569311", "FullCitation": "Gianni L, et al. J. Clin. Oncol. (2013) pmid: 23569311", "Include": "true"}, {"number": "145", "ReferenceId": "23397155", "FullCitation": "S\u00e1nchez_Rovira P, et al. Clin Transl Oncol (2013) pmid: 23397155", "Include": "true"}, {"number": "146", "ReferenceId": "23932548", "FullCitation": "Cameron D, et al. Lancet Oncol. (2013) pmid: 23932548", "Include": "true"}, {"number": "147", "ReferenceId": "24807156", "FullCitation": "Mok T, et al. J Thorac Oncol (2014) pmid: 24807156", "Include": "true"}, {"number": "148", "ReferenceId": "24577128", "FullCitation": "An SJ, et al. Cancer Gene Ther. (2014) pmid: 24577128", "Include": "true"}, {"number": "149", "ReferenceId": "29059426", "FullCitation": "Bais C, et al. J. Natl. Cancer Inst. (2017) pmid: 29059426", "Include": "true"}, {"number": "150", "ReferenceId": "19201650", "FullCitation": "Cohen EE, et al. Lancet Oncol. (2009) pmid: 19201650", "Include": "true"}, {"number": "151", "ReferenceId": "22565005", "FullCitation": "Van Cutsem E, et al. J. Clin. Oncol. (2012) pmid: 22565005", "Include": "true"}, {"number": "152", "ReferenceId": "29941486", "FullCitation": "Lee EQ, et al. Clin. Cancer Res. (2018) pmid: 29941486", "Include": "true"}, {"number": "153", "ReferenceId": "19826039", "FullCitation": "Xu L, et al. Cancer Res. (2009) pmid: 19826039", "Include": "true"}, {"number": "154", "ReferenceId": "25605928", "FullCitation": "Heist RS, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25605928", "Include": "true"}, {"number": "155", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "156", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "157", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "158", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "159", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "160", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "161", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "162", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "163", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "164", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "165", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "166", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "167", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "168", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "169", "ReferenceId": "25609015", "FullCitation": "Litchfield K, et al. Nat Commun (2015) pmid: 25609015", "Include": "true"}, {"number": "170", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "171", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "172", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "173", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "174", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "175", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "176", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "177", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "178", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "179", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "180", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "181", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "182", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "183", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "184", "ReferenceId": "8261392", "FullCitation": "Lothe RA, et al. Cancer Res. (1993) pmid: 8261392", "Include": "true"}, {"number": "185", "ReferenceId": "8033127", "FullCitation": "Murty VV, et al. Cancer Res. (1994) pmid: 8033127", "Include": "true"}, {"number": "186", "ReferenceId": "7669575", "FullCitation": "Huddart RA, et al. Br. J. Cancer (1995) pmid: 7669575", "Include": "true"}, {"number": "187", "ReferenceId": "11006028", "FullCitation": "Faulkner SW, et al. Gynecol. Oncol. (2000) pmid: 11006028", "Include": "true"}, {"number": "188", "ReferenceId": "11719586", "FullCitation": "Devouassoux_Shisheboran M, et al. Mol. Hum. Reprod. (2001) pmid: 11719586", "Include": "true"}, {"number": "189", "ReferenceId": "15492498", "FullCitation": "Velasco A, et al. Cancer Biol. Ther. (2004) pmid: 15492498", "Include": "true"}, {"number": "190", "ReferenceId": "16309235", "FullCitation": "Olasz J, et al. Anticancer Res. () pmid: 16309235", "Include": "true"}, {"number": "191", "ReferenceId": "25075023", "FullCitation": "Vladu\u0161i\u0107 T, et al. Anticancer Res. (2014) pmid: 25075023", "Include": "true"}, {"number": "192", "ReferenceId": "27153176", "FullCitation": "C\u00e1rcano FM, et al. Andrology (2016) pmid: 27153176", "Include": "true"}, {"number": "193", "ReferenceId": "12019150", "FullCitation": "Mayer F, et al. Cancer Res. (2002) pmid: 12019150", "Include": "true"}, {"number": "194", "ReferenceId": "18076065", "FullCitation": "Velasco A, et al. Int. J. Cancer (2008) pmid: 18076065", "Include": "true"}, {"number": "195", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "196", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "197", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "198", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "199", "ReferenceId": "12917328", "FullCitation": "Neuhaus P, et al. Mol. Cell. Biol. (2003) pmid: 12917328", "Include": "true"}, {"number": "200", "ReferenceId": "8663044", "FullCitation": "Ornitz DM, et al. J. Biol. Chem. (1996) pmid: 8663044", "Include": "true"}, {"number": "201", "ReferenceId": "1549352", "FullCitation": "Iida S, et al. Oncogene (1992) pmid: 1549352", "Include": "true"}, {"number": "202", "ReferenceId": "10945637", "FullCitation": "Ropiquet F, et al. Cancer Res. (2000) pmid: 10945637", "Include": "true"}, {"number": "203", "ReferenceId": "12399964", "FullCitation": "Niini T, et al. Leukemia (2002) pmid: 12399964", "Include": "true"}, {"number": "204", "ReferenceId": "2649847", "FullCitation": "Marics I, et al. Oncogene (1989) pmid: 2649847", "Include": "true"}, {"number": "205", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "206", "ReferenceId": "25950492", "FullCitation": "Parish A, et al. Cell Cycle (2015) pmid: 25950492", "Include": "true"}, {"number": "207", "ReferenceId": "12711740", "FullCitation": "Jonsson KB, et al. N. Engl. J. Med. (2003) pmid: 12711740", "Include": "true"}, {"number": "208", "ReferenceId": "11344269", "FullCitation": "Shimada T, et al. Proc. Natl. Acad. Sci. U.S.A. (2001) pmid: 11344269", "Include": "true"}, {"number": "209", "ReferenceId": "15863037", "FullCitation": "Yu X, et al. Cytokine Growth Factor Rev. (2005) pmid: 15863037", "Include": "true"}, {"number": "210", "ReferenceId": "24335106", "FullCitation": "Hughes TP, et al. Blood (2014) pmid: 24335106", "Include": "true"}, {"number": "211", "ReferenceId": "24650752", "FullCitation": "Takahashi N, et al. Biomark Res (2014) pmid: 24650752", "Include": "true"}, {"number": "212", "ReferenceId": "22357255", "FullCitation": "Reichardt P, et al. Ann. Oncol. (2012) pmid: 22357255", "Include": "true"}, {"number": "213", "ReferenceId": "22119758", "FullCitation": "Cauchi C, et al. Cancer Chemother. Pharmacol. (2012) pmid: 22119758", "Include": "true"}, {"number": "214", "ReferenceId": "22662203", "FullCitation": "Villar VH, et al. PLoS ONE (2012) pmid: 22662203", "Include": "true"}, {"number": "215", "ReferenceId": "25695690", "FullCitation": "Carvajal RD, et al. Clin. Cancer Res. (2015) pmid: 25695690", "Include": "true"}, {"number": "216", "ReferenceId": "26002753", "FullCitation": "Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2015) pmid: 26002753", "Include": "true"}, {"number": "217", "ReferenceId": "25882987", "FullCitation": "Blay JY, et al. Lancet Oncol. (2015) pmid: 25882987", "Include": "true"}, {"number": "218", "ReferenceId": "26722383", "FullCitation": "Kajimoto N, et al. Int J Clin Exp Pathol (2015) pmid: 26722383", "Include": "true"}, {"number": "219", "ReferenceId": "25221952", "FullCitation": "Sako H, et al. PLoS ONE (2014) pmid: 25221952", "Include": "true"}, {"number": "220", "ReferenceId": "16462496", "FullCitation": "Einhorn LH, et al. Am. J. Clin. Oncol. (2006) pmid: 16462496", "Include": "true"}, {"number": "221", "ReferenceId": "17976614", "FullCitation": "Pedersini R, et al. Lancet Oncol. (2007) pmid: 17976614", "Include": "true"}, {"number": "222", "ReferenceId": "20080832", "FullCitation": "Okamura A, et al. Ann. Oncol. (2010) pmid: 20080832", "Include": "true"}, {"number": "223", "ReferenceId": "16624552", "FullCitation": "Debiec_Rychter M, et al. Eur. J. Cancer (2006) pmid: 16624552", "Include": "true"}, {"number": "224", "ReferenceId": "16570351", "FullCitation": "Kamenz T, et al. World J. Gastroenterol. (2006) pmid: 16570351", "Include": "true"}, {"number": "225", "ReferenceId": "15650049", "FullCitation": "Wang YY, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15650049", "Include": "true"}, {"number": "226", "ReferenceId": "21415240", "FullCitation": "Oechsle K, et al. Ann. Oncol. (2011) pmid: 21415240", "Include": "true"}, {"number": "227", "ReferenceId": "19547919", "FullCitation": "Feldman DR, et al. Invest New Drugs (2010) pmid: 19547919", "Include": "true"}, {"number": "228", "ReferenceId": "25085632", "FullCitation": "Subbiah V, et al. J Hematol Oncol (2014) pmid: 25085632", "Include": "true"}, {"number": "229", "ReferenceId": "18955458", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955458", "Include": "true"}, {"number": "230", "ReferenceId": "26264378", "FullCitation": "Buchbinder EI, et al. Cancer (2015) pmid: 26264378", "Include": "true"}, {"number": "231", "ReferenceId": "26772734", "FullCitation": "Reichardt P, et al. BMC Cancer (2016) pmid: 26772734", "Include": "true"}, {"number": "232", "ReferenceId": "27073655", "FullCitation": "Hirai F, et al. Mol Clin Oncol (2016) pmid: 27073655", "Include": "true"}, {"number": "233", "ReferenceId": "20435347", "FullCitation": "Goemans BF, et al. Leuk. Res. (2010) pmid: 20435347", "Include": "true"}, {"number": "234", "ReferenceId": "22982658", "FullCitation": "Wakelee HA, et al. J Thorac Oncol (2012) pmid: 22982658", "Include": "true"}, {"number": "235", "ReferenceId": "21576636", "FullCitation": "Spigel DR, et al. J. Clin. Oncol. (2011) pmid: 21576636", "Include": "true"}, {"number": "236", "ReferenceId": "24420556", "FullCitation": "Sharma N, et al. Invest New Drugs (2014) pmid: 24420556", "Include": "true"}, {"number": "237", "ReferenceId": "22412143", "FullCitation": "Baselga J, et al. J. Clin. Oncol. (2012) pmid: 22412143", "Include": "true"}, {"number": "238", "ReferenceId": "22954665", "FullCitation": "Gradishar WJ, et al. Eur. J. Cancer (2013) pmid: 22954665", "Include": "true"}, {"number": "239", "ReferenceId": "19935794", "FullCitation": "Bengala C, et al. Br. J. Cancer (2010) pmid: 19935794", "Include": "true"}, {"number": "240", "ReferenceId": "20698202", "FullCitation": "Qun W, et al. Hepatogastroenterology () pmid: 20698202", "Include": "true"}, {"number": "241", "ReferenceId": "19089671", "FullCitation": "LaRocca RV, et al. J Gastrointest Cancer (2007) pmid: 19089671", "Include": "true"}, {"number": "242", "ReferenceId": "25446376", "FullCitation": "Moehler M, et al. Eur. J. Cancer (2014) pmid: 25446376", "Include": "true"}, {"number": "243", "ReferenceId": "21785998", "FullCitation": "Beardsley EK, et al. Invest New Drugs (2012) pmid: 21785998", "Include": "true"}, {"number": "244", "ReferenceId": "19154507", "FullCitation": "Aragon_Ching JB, et al. BJU Int. (2009) pmid: 19154507", "Include": "true"}, {"number": "245", "ReferenceId": "20443129", "FullCitation": "Reardon DA, et al. J. Neurooncol. (2011) pmid: 20443129", "Include": "true"}, {"number": "246", "ReferenceId": "23099651", "FullCitation": "Lee EQ, et al. Neuro_oncology (2012) pmid: 23099651", "Include": "true"}, {"number": "247", "ReferenceId": "23328813", "FullCitation": "Peereboom DM, et al. Neuro_oncology (2013) pmid: 23328813", "Include": "true"}, {"number": "248", "ReferenceId": "24786603", "FullCitation": "Hottinger AF, et al. Br. J. Cancer (2014) pmid: 24786603", "Include": "true"}, {"number": "249", "ReferenceId": "31492770", "FullCitation": "Lian B, et al. Oncologist (2019) pmid: 31492770", "Include": "true"}, {"number": "250", "ReferenceId": "18936790", "FullCitation": "Quint\u00e1s_Cardama A, et al. Nat Clin Pract Oncol (2008) pmid: 18936790", "Include": "true"}, {"number": "251", "ReferenceId": "19461405", "FullCitation": "Bisagni G, et al. J Thorac Oncol (2009) pmid: 19461405", "Include": "true"}, {"number": "252", "ReferenceId": "20372153", "FullCitation": "Handolias D, et al. Br. J. Cancer (2010) pmid: 20372153", "Include": "true"}, {"number": "253", "ReferenceId": "20970876", "FullCitation": "Di\u015fel U, et al. Lung Cancer (2011) pmid: 20970876", "Include": "true"}, {"number": "254", "ReferenceId": "22270258", "FullCitation": "Park SH, et al. Invest New Drugs (2012) pmid: 22270258", "Include": "true"}, {"number": "255", "ReferenceId": "24855380", "FullCitation": "Catania C, et al. Onco Targets Ther (2014) pmid: 24855380", "Include": "true"}, {"number": "256", "ReferenceId": "17699867", "FullCitation": "Guo T, et al. Clin. Cancer Res. (2007) pmid: 17699867", "Include": "true"}, {"number": "257", "ReferenceId": "18483300", "FullCitation": "Hu S, et al. Mol. Cancer Ther. (2008) pmid: 18483300", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_01_12 20:43:44", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "755x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "TESTIS", "disease_ontology": "Testis germ cell tumor (seminoma)", "flowcell_analysis": "2000019573", "gender": "male", "pathology_diagnosis": "Seminoma", "percent_tumor_nuclei": "60", "pipeline_version": "v3.9.0", "purity_assessment": "67.3", "specimen": "ORD_1269426_01*US1223968.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1269426_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Testis", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "789.82", "name": "SQ_US1223968.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.6746", "cds_effect": "1073C>G", "depth": "421", "equivocal": "false", "functional_effect": "missense", "gene": "CEBPA", "percent_reads": "67.46", "position": "chr19:33792248", "protein_effect": "A358G", "status": "unknown", "strand": "_", "transcript": "NM_004364", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"allele_fraction": "0.5171", "cds_effect": "245G>T", "depth": "876", "equivocal": "false", "functional_effect": "missense", "gene": "BARD1", "percent_reads": "51.71", "position": "chr2:215657140", "protein_effect": "G82V", "status": "unknown", "strand": "_", "transcript": "NM_000465", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"allele_fraction": "0.4927", "cds_effect": "3226A>G", "depth": "546", "equivocal": "false", "functional_effect": "missense", "gene": "EMSY", "percent_reads": "49.27", "position": "chr11:76255819", "protein_effect": "S1076G", "status": "unknown", "strand": "+", "transcript": "NM_020193", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"allele_fraction": "0.5186", "cds_effect": "3434A>T", "depth": "752", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3C2B", "percent_reads": "51.86", "position": "chr1:204408145", "protein_effect": "H1145L", "status": "unknown", "strand": "_", "transcript": "NM_002646", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"allele_fraction": "0.4741", "cds_effect": "1409C>A", "depth": "521", "equivocal": "false", "functional_effect": "missense", "gene": "FLT1", "percent_reads": "47.41", "position": "chr13:29001323", "protein_effect": "P470H", "status": "unknown", "strand": "_", "transcript": "NM_002019", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"allele_fraction": "0.4902", "cds_effect": "397G>A", "depth": "1073", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB4", "percent_reads": "49.02", "position": "chr2:212812179", "protein_effect": "E133K", "status": "unknown", "strand": "_", "transcript": "NM_005235", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"allele_fraction": "0.3716", "cds_effect": "2009T>G", "depth": "557", "equivocal": "false", "functional_effect": "missense", "gene": "MST1R", "percent_reads": "37.16", "position": "chr3:49934990", "protein_effect": "V670G", "status": "unknown", "strand": "_", "transcript": "NM_002447", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "10", "equivocal": "false", "gene": "CDKN1B", "number_of_exons": "3 of 3", "position": "chr12:12870773_12874150", "ratio": "2.97", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"copy_number": "8", "equivocal": "false", "gene": "RAD52", "number_of_exons": "11 of 11", "position": "chr12:1022522_1042247", "ratio": "2.77", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "PDGFRA", "number_of_exons": "22 of 22", "position": "chr4:55079414_55202195", "ratio": "2.46", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"copy_number": "8", "equivocal": "false", "gene": "CCND2", "number_of_exons": "5 of 5", "position": "chr12:4335813_4445571", "ratio": "2.64", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "KIT", "number_of_exons": "21 of 21", "position": "chr4:55475828_55651041", "ratio": "2.77", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"copy_number": "11", "equivocal": "false", "gene": "PTPRO", "number_of_exons": "27 of 27", "position": "chr12:15475633_15747987", "ratio": "3.27", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"copy_number": "8", "equivocal": "false", "gene": "FGF23", "number_of_exons": "3 of 3", "position": "chr12:4462589_4488748", "ratio": "2.25", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "KDR", "number_of_exons": "30 of 30", "position": "chr4:55896637_56038755", "ratio": "2.69", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"copy_number": "8", "equivocal": "false", "gene": "FGF6", "number_of_exons": "3 of 3", "position": "chr12:4494593_4598143", "ratio": "2.25", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"copy_number": "11", "equivocal": "false", "gene": "PIK3C2G", "number_of_exons": "31 of 31", "position": "chr12:18435015_18800962", "ratio": "3.34", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}, {"copy_number": "10", "equivocal": "false", "gene": "KRAS", "number_of_exons": "5 of 5", "position": "chr12:25344730_25448217", "ratio": "3.23", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}]}, "rearrangements": {"rearrangement": {"description": "PDGFRA(NM_006206) rearrangement exon 7", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "pos1": "chr4:55133747_55134015", "pos2": "chr4:61518351_61518628", "status": "unknown", "supporting_read_pairs": "134", "targeted_gene": "PDGFRA", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1223968.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}